Hyun Chin Cho

Hyun Chin Cho


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2024 in Applied Biological Chemistry
Verified
Journal Article
Open access
PDF file
SLSeung-Jun Lee
Seung-Jun Lee
KCKyoung Hwan Cho
Kyoung Hwan Cho
JKJong Cheol Kim
Jong Cheol Kim
HCHo Jin Choo
Ho Jin Choo
JHJeong-Yun Hwang
Jeong-Yun Hwang
YHYoung-Sool Hah
Young-Sool Hah
Obesity, a prevalent disease associated with numerous chronic conditions, including hyperlipidemia, hyperglycemia, diabetes, and metabolic syndrome, remains a major global health challenge. This study investigated the potential of green tea (GT), fermented tea (FT), and γ-aminobutyric acid (GABA) tea (GBT), which are rich in phytonutrients and polyphenols, for the management of obesity. Using a high-fat diet-induced obese mouse model (C57BL/6N), we explored the effect of these teas on various obesity-related parameters. The mice were categorized into five groups: normal diet with water, high-fat diet with water, and high-fat diet supplemented with GT, FT, or GBT. Over 13 weeks, we monitored body weight, perirenal and liver fat, adipocyte lipid accumulation, and key metabolic indicators, such as serum cholesterol, leptin, insulin, and fasting blood glucose. These teas contain beneficial phytochemicals such as GABA, theanine, and caffeine, and have demonstrated an enhanced antioxidant capacity, which increases the scavenging of free radicals and may reduce oxidative stress. The animal study indicated a decrease in feeding efficiency and significant reductions in body weight liver fat, epididymal fat, and perirenal fat, as well as in adipocyte lipid accumulation. Additionally, notable improvements were observed in metabolic health indicators, including reductions in serum cholesterol, leptin, insulin, and fasting blood glucose levels. Our findings revealed that GT, FT, or GBT significantly counteracted the negative effects of a high-fat diet, suggesting their potential in combating obesity and related metabolic disorders.

14 January 2021 in Applied Sciences
Verified
Journal Article
Open access
PDF file
YKYun-ji Kim
Yun-ji Kim
HCHyun Chin Cho
Hyun Chin Cho
HCHyun-chong Cho
Hyun-chong Cho
Gastric cancer has a high mortality rate worldwide, but it can be prevented with early detection through regular gastroscopy. Herein, we propose a deep learning-based computer-aided diagnosis (CADx) system applying data augmentation to help doctors classify gastroscopy images as normal or abnormal. To improve the performance of deep learning, a large amount of training data are required. However, the collection of medical data, owing to their nature, is highly expensive and time consuming. Therefore, data were generated through deep convolutional generative adversarial networks (DCGAN), and 25 augmentation policies optimized for the CIFAR-10 dataset were implemented through AutoAugment to augment the data. Accordingly, a gastroscopy image was augmented, only high-quality images were selected through an image quality-measurement method, and gastroscopy images were classified as normal or abnormal through the Xception network. We compared the performances of the original training dataset, which did not improve, the dataset generated through the DCGAN, the dataset augmented through the augmentation policies of CIFAR-10, and the dataset combining the two methods. The dataset combining the two methods delivered the best performance in terms of accuracy (0.851) and achieved an improvement of 0.06 over the original training dataset. We confirmed that augmenting data through the DCGAN and CIFAR-10 augmentation policies is most suitable for the classification model for normal and abnormal gastric endoscopy images. The proposed method not only solves the medical-data problem but also improves the accuracy of gastric disease diagnosis.

20 April 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
GKGi-Ae Kim
Gi-Ae Kim
HCHyun Chin Cho
Hyun Chin Cho
SJSoung Won Jeong
Soung Won Jeong
BKBo-kyeong Kang
Bo-kyeong Kang
MKMimi Kim
Mimi Kim
DJDae Won Jun
Dae Won Jun
Preclinical data have shown that the herbal extract, ALS-L1023, from Melissa officinalis reduces visceral fat and hepatic steatosis. We aimed to assess the safety and efficacy of ALS-L1023 as the treatment of non-alcoholic fatty liver disease (NAFLD). We conducted a 24-week randomized, double-blind, placebo-controlled 2a study in patients with NAFLD (MRI-proton density fat fraction [MRI-PDFF] ≥ 8% and liver fibrosis ≥ 2.5 kPa on MR elastography [MRE]) in Korea. Patients were randomly assigned to 1800 mg ALS-L1023 (n = 19), 1200 mg ALS-L1023 (n = 21), or placebo (n = 17) groups. Efficacy endpoints included changes in liver fat on MRI-PDFF, liver stiffness on MRE, and liver enzymes. For the full analysis set, a relative hepatic fat reduction from baseline was significant in the 1800 mg ALS-L1023 group (−15.0%, p = 0.03). There was a significant reduction in liver stiffness from baseline in the 1200 mg ALS-L1023 group (−10.7%, p = 0.03). Serum alanine aminotransferase decreased by −12.4% in the 1800 mg ALS-L1023 group, −29.8% in the 1200 mg ALS-L1023 group, and −4.9% in the placebo group. ALS-L1023 was well tolerated and there were no differences in the incidence of adverse events among the study groups. ALS-L1023 could reduce hepatic fat content in patients with NAFLD.

16 December 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
CLChang-Min Lee
Chang-Min Lee
SKSeong-Je Kim
Seong-Je Kim
JCJungWoo Choi
JungWoo Choi
HCHyun Chin Cho
Hyun Chin Cho
OLOk Jae Lee
Ok Jae Lee
Background/Objectives: Bismuth quadruple therapy (BQT) is recommended as the best second-line regimen after failure of first-line clarithromycin triple therapy (CTT) for Helicobacter pylori eradication. However, there are some limitations to this approach, including the lack of an appropriate sequel regimen after failure of BQT and complicated administration. Metronidazole triple therapy (MTT) is simple to administer, but it is not widely recommended. This study was conducted to determine the efficacy of MTT as second-line regimen for H. pylori eradication after failure of CTT. Methods: We retrospectively reviewed the medical records of the Korean patients with H. pylori infection who underwent second-line treatment after failure of first-line CTT from October 2013 to October 2019. The efficacy of MTT and BQT for H. pylori eradication was compared. Results: The eradication rate in the BQT group tended to be higher than that in the MTT group; however, the difference was not statistically significant (208/233, 89.3% versus 244/284, 85.9%, p = 0.287). Among 40 patients with second-line MTT eradication failure, 21 received the third-line BQT, and 15 showed successful eradication (15/21, 71.4%). In the men 70 years or older, the eradication rate of MTT was lower than that of BQT without statistical significance (75.8% versus 94.1%, p = 0.141). Conclusions: These findings suggested that MTT could be a second-line treatment option, reserving BQT for Helicobacter pylori eradication after first line CTT failure, except in elderly men 70 years or older.

10 September 2026 in Cancers
Verified
Journal Article
Open access
PDF file
YSYoungEun Seo
YoungEun Seo
CBChan Joong Bae
Chan Joong Bae
WLWon Jae Lee
Won Jae Lee
SCSun Young Chun
Sun Young Chun
JYJun Sik Yoon
Jun Sik Yoon
SCSung Bum Cho
Sung Bum Cho
Background/Objectives: Real-world data in high-risk patients remain limited; this study evaluated survival, safety, and prognostic factors in this patient group. Methods: This multicenter study retrospectively reviewed 783 patients who received Ate/Bev from 2022–2024 across South Korea. High-risk patients (n = 252, 32.2%) were defined by main portal vein tumor thrombus (Vp4), tumor occupancy ≥50% of liver volume, or bile duct invasion. Propensity score matching (PSM) was performed to balance host-related factors between the high-risk and non-high-risk (n = 531) groups. Results: After PSM (251 pairs, n = 502), overall survival (median 10.4 vs. 14.9 months; HR 1.57, 95% CI 1.28–1.92, p < 0.001) and progression-free survival (median 6.0 vs. 6.8 months; HR 1.29, 95% CI 1.08–1.53, p = 0.009) remained significantly worse in the high-risk group. Objective response (25.1% vs. 19.9%, p = 0.200) and disease control rates (71.7% vs. 76.5%, p = 0.262) were comparable. Among 103 responders with documented response-onset dates, an exploratory complete-case analysis showed a numerically shorter duration of response in the high-risk group, although the difference did not reach statistical significance (median, 7.1 vs. 11.3 months; HR, 1.57; 95% CI, 0.97–2.55; p = 0.065). Conclusions: Ate/Bev achieved similar antitumor response rates in high-risk and non-high-risk patients, but survival remained poorer in the high-risk group. High-risk status therefore did not preclude antitumor activity with Ate/Bev.